BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 19910427)

  • 41. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
    Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
    J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative evaluation of the new GRPR-antagonist
    Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
    J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
    Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
    Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
    Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells.
    Aprikian AG; Han K; Chevalier S; Bazinet M; Viallet J
    J Mol Endocrinol; 1996 Jun; 16(3):297-306. PubMed ID: 8782088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
    Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
    Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ; Sieckman GL; Owen NK; Hayes DL; Mazuru DG; Volkert WA; Hoffman TJ
    Anticancer Res; 2003; 23(1A):63-70. PubMed ID: 12680195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
    Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
    J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.
    Chen J; Linder KE; Cagnolini A; Metcalfe E; Raju N; Tweedle MF; Swenson RE
    Appl Radiat Isot; 2008 Apr; 66(4):497-505. PubMed ID: 18178448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
    J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
    Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
    Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.
    Nock BA; Nikolopoulou A; Galanis A; Cordopatis P; Waser B; Reubi JC; Maina T
    J Med Chem; 2005 Jan; 48(1):100-10. PubMed ID: 15634004
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
    Ferro-Flores G; Arteaga de Murphy C; Rodriguez-Cortés J; Pedraza-López M; Ramírez-Iglesias MT
    Nucl Med Commun; 2006 Apr; 27(4):371-6. PubMed ID: 16531924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
    Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
    Fozing T; Scheuer C; Samnick S
    Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
    Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS
    Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
    Yang YS; Zhang X; Xiong Z; Chen X
    Nucl Med Biol; 2006 Apr; 33(3):371-80. PubMed ID: 16631086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isolation of a 177Hf complex formed by beta-decay of a 177Lu-labeled radiotherapeutic compound and NMR structural elucidation of the ligand and its Lu and Hf complexes.
    Cagnolini A; D'Amelio N; Metcalfe E; Nguyen HD; Aime S; Swenson RE; Linder KE
    Inorg Chem; 2009 Apr; 48(7):3114-24. PubMed ID: 19243162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.